408 related articles for article (PubMed ID: 26627075)
21. Efficacy comparison of ustekinumab between anti-tumor necrosis factor-α drug-naïve and anti-tumor necrosis factor-α drug-resistant Japanese psoriasis cases.
Takahashi N; Noda S; Taniguchi T; Adachi M
Int J Dermatol; 2015 Oct; 54(10):1194-8. PubMed ID: 26016819
[TBL] [Abstract][Full Text] [Related]
22. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.
Lebwohl M; Strober B; Menter A; Gordon K; Weglowska J; Puig L; Papp K; Spelman L; Toth D; Kerdel F; Armstrong AW; Stingl G; Kimball AB; Bachelez H; Wu JJ; Crowley J; Langley RG; Blicharski T; Paul C; Lacour JP; Tyring S; Kircik L; Chimenti S; Callis Duffin K; Bagel J; Koo J; Aras G; Li J; Song W; Milmont CE; Shi Y; Erondu N; Klekotka P; Kotzin B; Nirula A
N Engl J Med; 2015 Oct; 373(14):1318-28. PubMed ID: 26422722
[TBL] [Abstract][Full Text] [Related]
23. Long-term therapy with ustekinumab for psoriasis in a patient with a history of malignant melanoma.
Gkalpakiotis S; Arenberger P; Fridman M; Arenbergerova M
Dermatol Ther; 2017 Nov; 30(6):. PubMed ID: 28730674
[No Abstract] [Full Text] [Related]
24. Correlation Between Dermatology Life Quality Index and Psoriasis Area and Severity Index in Patients with Psoriasis Treated with Ustekinumab.
Hesselvig JH; Egeberg A; Loft ND; Zachariae C; Kofoed K; Skov L
Acta Derm Venereol; 2018 Mar; 98(3):335-339. PubMed ID: 29110019
[TBL] [Abstract][Full Text] [Related]
25. Response to Secukinumab after Treatment Failure with Ustekinumab in 6 Patients with Plaque Psoriasis.
Morgado-Carrasco D; Riera-Monroig J; Fustà-Novell X; Alsina Gibert M
Actas Dermosifiliogr (Engl Ed); 2018; 109(6):565-567. PubMed ID: 29169562
[No Abstract] [Full Text] [Related]
26. Inadvertent pregnancy during ustekinumab therapy in a patient with plaque psoriasis and impetigo herpetiformis.
Alsenaid A; Prinz JC
J Eur Acad Dermatol Venereol; 2016 Mar; 30(3):488-90. PubMed ID: 25413895
[No Abstract] [Full Text] [Related]
27. Skin and nail responses after 1 year of infliximab therapy in patients with moderate-to-severe psoriasis: a retrospective analysis of the EXPRESS Trial.
Reich K; Ortonne JP; Kerkmann U; Wang Y; Saurat JH; Papp K; Langley R; Griffiths CE
Dermatology; 2010; 221(2):172-8. PubMed ID: 20628238
[TBL] [Abstract][Full Text] [Related]
28. Different Responses to Ustekinumab of Two HLA-Cw6-positive Homozygous Twins with Psoriasis.
Burlando M; Cozzani E; Campisi C; Di Costanzo A; Parodi A
Acta Derm Venereol; 2016 Aug; 96(6):858-9. PubMed ID: 26714660
[No Abstract] [Full Text] [Related]
29. Safety of ustekinumab in severe psoriasis with chronic hepatitis B.
Raymundo AR; Facin AP; Silva de Castro CC; Faria AR
Indian J Dermatol Venereol Leprol; 2016; 82(3):326-8. PubMed ID: 27088944
[No Abstract] [Full Text] [Related]
30. Persistence of interleukin (IL)-17A+ T lymphocytes and IL-17A expression in treatment-resistant psoriatic plaques despite ustekinumab therapy.
Jack C; Mashiko S; Arbour N; Bissonnette R; Sarfati M
Br J Dermatol; 2017 Jul; 177(1):267-270. PubMed ID: 27599204
[No Abstract] [Full Text] [Related]
31. Antinuclear antibody formation following administration of anti-tumor necrosis factor agents in Japanese patients with psoriasis.
Yanaba K; Umezawa Y; Honda H; Sato R; Chiba M; Kikuchi S; Asahina A; Nakagawa H
J Dermatol; 2016 Apr; 43(4):443-4. PubMed ID: 26662275
[No Abstract] [Full Text] [Related]
32. Characteristics of patients receiving ustekinumab compared with secukinumab for treatment of moderate-to-severe plaque psoriasis - nationwide results from the DERMBIO registry.
Egeberg A; Iversen L; Gniadecki R; Hvid L; Dam TN; Bryld LE; Skov L
J Eur Acad Dermatol Venereol; 2017 Jul; 31(7):1183-1187. PubMed ID: 28273375
[TBL] [Abstract][Full Text] [Related]
33. Ustekinumab: when everything else fails?
Vitiello M; Grant A; Kerdel FA
Int J Dermatol; 2011 Apr; 50(4):478-82. PubMed ID: 21413963
[No Abstract] [Full Text] [Related]
34. No evidence for induction of autoantibodies or autoimmunity during treatment of psoriasis with ustekinumab.
Rodríguez-Jiménez P; Chicharro P; Godoy A; Llamas-Velasco M; García M; Daudén E
Br J Dermatol; 2017 Sep; 177(3):862-863. PubMed ID: 28508387
[No Abstract] [Full Text] [Related]
35. Absolute Versus Relative Psoriasis Area and Severity Index in Clinical Practice.
Del Alcázar Viladomiu E; Lamas Doménech N; Salleras Redonnet M
Actas Dermosifiliogr (Engl Ed); 2019 Sep; 110(7):606-610. PubMed ID: 30803689
[No Abstract] [Full Text] [Related]
36. Drugs for psoriasis.
Med Lett Drugs Ther; 2019 Jun; 61(1574):89-96. PubMed ID: 31381544
[No Abstract] [Full Text] [Related]
37. Brodalumab: A Review of Safety.
Rusta-Sallehy S; Gooderham M; Papp K
Skin Therapy Lett; 2018 Mar; 23(2):1-3. PubMed ID: 29562088
[TBL] [Abstract][Full Text] [Related]
38. Ustekinumab treats psoriasis refractory to seven conventional and biologic therapies.
Rallis E; Verros CD
Dermatol Online J; 2011 Apr; 17(4):14. PubMed ID: 21549089
[No Abstract] [Full Text] [Related]
39. Antibodies in the Treatment of Psoriasis: IL-12/23 p40 and IL-17a.
Leonardi CL
Semin Cutan Med Surg; 2016 Jun; 35(4 Suppl 4):S74-7. PubMed ID: 27551698
[TBL] [Abstract][Full Text] [Related]
40. Clearance of annular pustular psoriasis with ustekinumab.
Schnabel V; Broekaert SMC; Schön MP; Mössner R
Eur J Dermatol; 2017 Jun; 27(3):296-297. PubMed ID: 28202422
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
